CLOVER CORPORATION LIMITED (CLV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CLV

CLV - CLOVER CORPORATION LIMITED

FNArena Sector : Health & Nutrition
Year End: July
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.21
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.705

02 Oct
2025

0.000

OPEN

$0.72

0.000

HIGH

$0.72

181,639

LOW

$0.69

TARGET
$0.75 6.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . EXL . MCP . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS
CLV: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 4.2 4.0 xxx
DPS (cps) xxx 1.8 2.0 xxx
EPS Growth xxx 100.0% - 4.8% xxx
DPS Growth xxx 100.0% 14.3% xxx
PE Ratio xxx N/A 17.3 xxx
Dividend Yield xxx N/A 2.9% xxx
Div Pay Ratio(%) xxx 41.7% 50.0% xxx

Dividend yield today if purchased 3 years ago: 1.39%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.54

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 30/10 - ex-div 0.75c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx4.2
DPS All xxxxxxxxxxxxxxx1.8
Sales/Revenue xxxxxxxxxxxxxxx86.0 M
Book Value Per Share xxxxxxxxxxxxxxx43.3
Net Operating Cash Flow xxxxxxxxxxxxxxx8.3 M
Net Profit Margin xxxxxxxxxxxxxxx8.16 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx10.07 %
Return on Invested Capital xxxxxxxxxxxxxxx9.55 %
Return on Assets xxxxxxxxxxxxxxx8.20 %
Return on Equity xxxxxxxxxxxxxxx10.07 %
Return on Total Capital xxxxxxxxxxxxxxx13.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx4.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx2 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx9 M
Price To Book Value xxxxxxxxxxxxxxx1.28

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx1.56 %
Cost of Goods Sold xxxxxxxxxxxxxxx60 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx16 M
Research & Development xxxxxxxxxxxxxxx3 M
Investments - Total xxxxxxxxxxxxxxx11 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

24/09/2025

1

Buy

$0.75

6.38%

The highlight of Clover's FY25 result, in UBS' view, was a strong 39% y/y sales growth in 2H, beating its expectation by 6%, along with sequential gross margin expansion and solid cost management.

This helped offset the softer tone for 1H26, with sales for the first four months (including forward orders) expected to be flat, missing the broker's expectation for 8% growth. Pull-forward of infant milk formula orders to 4Q25 was likely the reason.

The broker cut FY26 sales forecast by -4% to $87m but factored in higher gross margin and tighter opex. As a result, EPS forecasts for FY26-28 rise by 5-6%.

Buy. Target lifted to 75c from 68c.

FORECAST
UBS forecasts a full year FY26 dividend of 2.00 cents and EPS of 4.00 cents.
UBS forecasts a full year FY27 dividend of 2.00 cents and EPS of 5.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Taylor Collison

19/05/2025

1

Speculative Buy

-

-

Taylor Collison has revisited its Speculative Buy rating on Clover and assesses it to be undervalued for a business with potential tailwinds. 

One key development since March is Soul Pattinson ((SOL)) selling out its entire stake in the company, removing an overhang on the stock.

The broker also notes major customer Danone reported 9.9% like-for-like sales growth in China in 1Q25. Strong growth was also seen in its specialist nutrition division across China and Europe, with Nutrison sales likely to benefit the company.

No change to forecasts. Speculative Buy retained. No target price.

FORECAST
Taylor Collison forecasts a full year FY26 dividend of 1.80 cents and EPS of 4.90 cents.
Access Extra Coverage Research History >

CLV STOCK CHART

FNArena News on CLV

Latest Health & Nutrition News

1
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
2
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
3
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
4
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
5
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
6
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
7
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
8
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
9
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
10
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia